Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Insiders Buying Charter Communications And 2 Other Stocks

Published 02/02/2023, 11:30
Updated 02/02/2023, 12:40
© Reuters.  Insiders Buying Charter Communications And 2 Other Stocks

© Reuters. Insiders Buying Charter Communications And 2 Other Stocks

Benzinga - Although US stocks closed higher on Wednesday, there were a few notable insider trades.

When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision.

Below is a look at a few recent notable insider purchases. For more, check out Benzinga's insider transactions platform.

Charter Communications

The Trade: Charter Communications, Inc. (NASDAQ: CHTR) Director Steven A Miron acquired a total of 2,500 shares an average price of $384.35. To acquire these shares, it cost around $960.87 thousand.

What’s Happening: Charter Communications reported worse-than-expected Q4 EPS and sales results.

What Charter Communications Does: Charter is the product of the 2016 merger of three cable companies, each with a decades-long history in the business: Legacy Charter, Time Warner Cable, and Bright House Networks.

Mid Penn Bancorp

The Trade: Mid Penn Bancorp, Inc. (NASDAQ: MPB) Director John E Noone acquired a total of 2,000 shares at an average price of $30.69. To acquire these shares, it cost around $61.38 thousand.

What’s Happening: Mid Penn Bancorp reported upbeat quarterly earnings.

What Mid Penn Bancorp Does: Mid Penn Bancorp Inc operates in the financial services domain.

Don’t forget to check out our premarket coverage here

NGM Biopharmaceuticals

The Trade: NGM Biopharmaceuticals, Inc. (NASDAQ: NGM) 10% owner TCG Opportunity III GP, LLC bought a total of 184,272 shares at an average price of $5.00. To acquire these shares, it cost around $921.11 thousand.

What’s Happening: NGM Bio, last month, outlines corporate strategy and issued guidance on key priorities.

What NGM Biopharmaceuticals Does: NGM Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company.

Check This Out: 5 Most Expensive Materials Stocks You Should Worry About

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.